Founded in 2006, Cytonics is a private research and development company focused on creating molecular diagnostics and therapeutics for chronic musculoskeletal diseases, with a particular emphasis on osteoarthritis (OA). The company's flagship product, the Fibronectin-Aggrecan Complex Test ("FACT"), quantifies the degree of cartilage damage in painful and inflamed joints, aiding physicians in determining the most appropriate course of treatment. Formation of the Fibronectin-Aggrecan Complex points to the molecular pathogenesis of OA, which is driven by protease-mediated degradation of the cartilage tissue. This led Cytonics to develop disease-modifying therapies for OA, predicated on the understanding that multiple proteases are responsible for the majority of cartilage damage in OA, and an effective therapy must have broad-spectrum anti-protease activity.

Cytonics' first-generation treatment for osteoarthritis was the Autologous Platelet-Integrated Concentrate (APIC) system. This 510(k) medical device selectively concentrates a therapeutic blood protein called alpha-2-macroglobulin (A2M) from patients' own blood, preparing the A2M-rich concentrate for direct injection into damaged, arthritic joints. The APIC therapy, which leverages the anti-protease activity of the endogenous A2M protein, has treated thousands of patients to date, demonstrating the clinical and commercial viability of A2M as a treatment for OA.

Building on this success, Cytonics is now developing a recombinant A2M variant called "CYT-108." Engineered to more potently inhibit cartilage-degrading proteases, CYT-108 is up to 200% more effective than the natural A2M molecule in reducing cartilage damage and joint membrane inflammation. If approved by the FDA, CYT-108 may be the first (and only) disease-modifying treatment for osteoarthritis. Cytonics has raised over $25 million in private funding and received $1.8 million in grants from the NIH to support their groundbreaking research. Learn more at www.cytonics.com.

Industries

Health
Biotechnology
Pharmaceuticals

Office Locations

658 W. Indiantown Road, Suite 214, Jupiter, FL 33458